ZELTIQ COOLSCULPTING

K120023 · Zeltiq Aesthetics, Inc. · OOK · May 2, 2012 · General, Plastic Surgery

Device Facts

• Record ID: K120023
• Device Name: ZELTIQ COOLSCULPTING
• Applicant: Zeltiq Aesthetics, Inc.
• Product Code: OOK · General, Plastic Surgery
• Decision Date: May 2, 2012
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 878.4340
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The CoolSculpting System is a skin cooling or heating device. The device is indicated for cold-assisted lipolysis of the abdomen, as well as the flank, or "love handles" in individuals with a Body Mass Index (BMI) of 30 or less. The device is intended to affect the appearance of the abdomen and the flank. Cooling with the device may also be used to minimize pain and thermal injury during laser and dermatological treatments and act as a local anesthetic for procedures that induce minor local discomfort. The CoolSculpting System is also indicated for use to provide localized thermal therapy (hot or cold) to minimize pain post-trauma and post-surgery, and for temporary relief of minor aches, pains, and muscle spasms. The optional massage function can also be used for the temporary relief of minor muscle aches, pain, and spasm, for temporary improvement in local circulation and temporary reduction in the appearance of cellulite. The ZELTIQ Gelpad facilitates thermal contact of the device with a patient's skin by mitigating minor variances in device-to-skin contact.

Device Story

Thermoelectric cooling/heating device; applies controlled thermal energy to treatment site; includes optional massage feature; uses ZELTIQ Gelpad for skin contact. Operated by clinicians in aesthetic/dermatological settings. Device induces lipolysis of subcutaneous fat; provides localized thermal therapy for pain/spasms. Clinical benefit: non-invasive fat reduction, pain relief, and improved appearance of abdomen/flank. Healthcare providers use visual assessment and patient feedback to evaluate outcomes.

Clinical Evidence

Prospective multicenter study; 60 subjects; abdominal subcutaneous fat reduction. Treatment: 60 minutes at Cooling Intensity Factor (CIF) 42 (72.9 mW/cm²). Primary endpoint: photographic evaluation by 3 blinded evaluators at 16 weeks; 85% correct baseline identification (statistically significant). Confirmed by ultrasound and patient surveys. No serious adverse events; no changes in lipid profile or liver function.

Technological Characteristics

Thermoelectric cooling/heating system; provides controlled thermal energy. Includes optional massage feature. Uses ZELTIQ Gelpad for thermal interface. Operates via Cooling Intensity Factor (CIF) settings.

Indications for Use

Indicated for cold-assisted lipolysis of abdomen and flank in individuals with BMI ≤ 30; localized thermal therapy for post-trauma/post-surgery pain, minor aches, pains, and muscle spasms; skin cooling to minimize pain/thermal injury during laser/dermatological procedures; optional massage for minor muscle aches, pain, spasms, local circulation improvement, and cellulite appearance reduction.

Regulatory Classification

Identification

A contact cooling system for aesthetic use is a device that is a combination of a cooling pad associated with a vacuum or mechanical massager intended for the disruption of adipocyte cells intended for non-invasive aesthetic use.

Special Controls

*Classification.* Class II (special controls). The special controls for this device is FDA's “Guidance for Industry and FDA Staff; Class II Special Controls Guidance Document: Contact Cooling System for Aesthetic Use.” See § 878.1(e) for the availability of this guidance document.

Predicate Devices

• ZELTIQ Dermal Cooling Device (K080521)
• ZELTIQ System (K090094)

Submission Summary (Full Text)

{0}------------------------------------------------

K12.0023 1/2

MAY - 2 2012

# 510(K) SUMMARY OF SAFETY AND EFFECTIVENESS

This 510(k) summary of safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

| APPLICANT: | ZELTIQ™ Aesthetics, Inc.<br>4698 Willow Road<br>Pleasanton, CA 94588 |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TRADE NAME: | ZELTIQ CoolSculpting |
| COMMON NAME: | Skin Cooling Device |
| CLASSIFICATION<br>NAME: | Contact Cooling System for Aesthetic Use |
| DEVICE<br>CLASSIFICATION: | Class II, 21 CFR §878.4340 |
| PRODUCT CODE: | OOK |
| PREDICATE<br>DEVICE: | The ZELTIQ CoolSculpting device is substantially equivalent to the<br>ZELTIQ Dermal Cooling Device, cleared as K080521, and also known<br>as the ZELTIQ Lipolysis System and the ZELTIQ System (K090094). |

#### SUBSTANTIALLY EQUIVALENT TO:

The ZELTIQ CoolSculpting System is substantially equivalent to the ZELTIQ Dermal Cooling Device (K080521), also known as the ZELTIQ CoolSculpting System, which has been cleared for the indication of cold-assisted lipolysis of the flank (love handle). It is also substantially equivalent to the ZELTIQ System (K090094) which has been cleared for the indication of a skin cooling device to minimize pain and thermal injury during laser and dermatological treatments.

### DESCRIPTION OF THE DEVICE SUBJECT TO PREMARKET NOTIFICATION:

The CoolSculpting System is a thermoelectric cooling and heating device that applies controlled cooling or heating to a treatment site. The device includes an optional massage feature.

#### INDICATION FOR USE:

The CoolSculpting System is a skin cooling or heating device. The device is indicated for cold-assisted lipolysis of abdomen, as well as the flank, or "love handles" in individuals with a Body Mass Index (BMI) of 30 or less. The device is intended to affect the appearance of the abdomen and the flank. Cooling with the device may also be used to minimize pain and thermal injury during laser and dermatological treatments and act as a local anesthetic for procedures that induce minor local discomfort.

{1}------------------------------------------------

K120623 2/2

The CoolSculpting System is also indicated for use to provide localized thermal therapy (hot or cold) to minimize pain post-trauma and post-surgery, and for temporary relief of minor aches, pains, and muscle spasms. The optional massage function can also be used for the temporary relief of minor muscle aches, pain, and spasm, for temporary improvement in local circulation and temporary reduction in the appearance of cellulite. The ZELTIQ Gelpad facilitates thermal contact of the device with a patient's skin by mitigating minor variances in device-to-skin contact.

#### TECHNICAL CHARACTERISTICS:

The CoolSculpting System is a thermoelectric cooling and heating device that applies controlled cooling or heating to a treatment site. The device also provides an optional massage feature.

### PERFORMANCE DATA:

Animal data has been used to establish device safety and preferential selectivity of the CoolSculpting System for fat cells without damaging surrounding normal skin and muscle.

## CLINICAL PERFORMANCE:

A prospective multicenter clinical study was conducted to evaluate the use of the ZELTIO System for subcutaneous fat reduction in the abdominal area. Sixty (60) subjects were treated with the ZELTIQ System at CIF 42 (a Cooling Intensity Factor setting of 42 corresponds to 72.9 mW/cm² of heat extracted from the body) over 60 minutes. The optional massage feature was not used as part of this study.

The primary endpoint was the photographic evaluation by three independent blinded evaluators at the 16 week follow-up. The evaluators correctly identified the baseline image 85% of the time and the result was statistically significant. Fat layer reduction in the abdomen was further confirmed by overall positive patient survey results and statistically significant ultrasound results. Lipid profile and liver function tests conducted at several points post-treatment showed no discernible difference from baseline. No serious adverse events were reported. Results from the clinical study support safe and effective use of the device for cold-assisted lipolysis of the abdomen.

## BASIS FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE:

Clinical testing has demonstrated the ability of the CoolSculpting System to cause lipolysis of the subcutaneous fat in the abdomen in the same way that lipolysis occurs when the device is used in the flank. The device is used in the same way and with equivalent settings and use parameters as when used for treatment of the flank.

There has been no substantial change to the device design or operating principles from those of the previously cleared device for a similar indication. For that reason, bench testing was not required to demonstrate that the device is functionally equivalent to the predicate devices regarding design or operating principles.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular pattern around the eagle. The eagle is composed of three curved lines that form the shape of the bird's body and wings. The text is in a simple, sans-serif font.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

ZELTIO Aesthetics, Inc. % Mr. Louis-Pierre Marcoux Director of Regulatory Affairs 4698 Willow Road Pleasanton, California 94115

JUN - 1 2012

Re: K120023

Trade/Device Name: ZELTIQ CoolSculpting Regulation Number: 21 CFR 878.4340 Regulation Name: Contact cooling system for aesthetic use Regulatory Class: II Product Code: OOK Dated: April 20, 2012 Received: April 23, 2012

Dear Mr. Marcoux:

This letter corrects our substantially equivalent letter of May 2, 2012.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

{3}------------------------------------------------

Page 2 - Mr. Louis-Pierre Marcoux

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours.

y yours,

Melkerson

Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

# 4. INDICATIONS FOR USE STATEMENT

510(k) Number (if known): K120023

Device Name: ZELTIO CoolSculpting

Indications for Use:

The CoolSculpting System is a skin cooling or heating device. The device is indicated for cold-assisted lipolysis of the abdomen, as well as the flank, or "love handles" in individuals with a Body Mass Index (BMI) of 30 or less. The device is intended to affect the appearance of the abdomen and the flank. Cooling with the device may also be used to minimize pain and thermal injury during laser and dermatological treatments and act as a local anesthetic for procedures that induce minor local discomfort.

The CoolSculpting System is also indicated for use to provide localized thermal therapy (hot or cold) to minimize pain post-trauma and post-surgery, and for temporary relief of minor aches, pains, and muscle spasms. The optional massage function can also be used for the temporary relief of minor muscle aches, pain, and spasm, for temporary improvement in local circulation and temporary reduction in the appearance of cellulite.

The ZELTIO Gelpad facilitates thermal contact of the device with a patient's skin by mitigating minor variances in device-to-skin contact.

Prescription Use x (Part 21 CFR 801 Subpart D)

· 510(k) Number

AND/OR

Over-The-Counter Use _ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Neil R. Ogden for mxm
(Division Sign-Off)
Division of Surgical, Orthopedic,
and Restorative Devices